172 related articles for article (PubMed ID: 26062696)
1. Tumor marker CA 15-3 in breast cancer patients.
Fejzić H; Mujagić S; Azabagić S; Burina M
Acta Med Acad; 2015; 44(1):39-46. PubMed ID: 26062696
[TBL] [Abstract][Full Text] [Related]
2. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
Gedik GK; Kiratli PO; Tascioglu B; Aras T
Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
[TBL] [Abstract][Full Text] [Related]
5. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.
Viot J; Bachour M; Meurisse A; Pivot X; Fiteni F
Breast; 2017 Aug; 34():53-57. PubMed ID: 28505557
[TBL] [Abstract][Full Text] [Related]
7. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
[TBL] [Abstract][Full Text] [Related]
8. Ca 15-3 in the follow-up of localised breast cancer: a prospective study.
Kokko R; Holli K; Hakama M
Eur J Cancer; 2002 Jun; 38(9):1189-93. PubMed ID: 12044504
[TBL] [Abstract][Full Text] [Related]
9. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
10. Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?
Jäger W; Kissing A; Cilaci S; Melsheimer R; Lang N
Br J Cancer; 1994 Sep; 70(3):493-5. PubMed ID: 8080736
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
[TBL] [Abstract][Full Text] [Related]
12. The relation between tumor marker Ca 15-3 and metastases in interpectoral lymph nodes in breast cancer patients.
Vrdoljak DV; Knezevic F; Ramljak V
Saudi Med J; 2006 Apr; 27(4):460-2. PubMed ID: 16598320
[TBL] [Abstract][Full Text] [Related]
13. Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
Mathew J; Prinsloo P; Agrawal A; Gutteridge E; Marenah C; Robertson JF; Cheung KL
Breast; 2014 Oct; 23(5):567-72. PubMed ID: 24874285
[TBL] [Abstract][Full Text] [Related]
14. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients.
Pichon MF; Hacene K; Guepratte S; Neumann R
Clin Lab; 2004; 50(3-4):163-70. PubMed ID: 15074470
[TBL] [Abstract][Full Text] [Related]
15. [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases].
del Rocío Estrada-Sánchez G; Mireles Enríquez M; Valverde Castañeda N
Rev Invest Clin; 2003; 55(4):412-8. PubMed ID: 14635605
[TBL] [Abstract][Full Text] [Related]
16. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
Oremek G; Sauer-Eppel H; Klepzig M
Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of serum cancer antigen 15-3 in breast cancer patients with isolated bone metastases.
Turanli S; Cetin A
Biomarkers; 2010 Aug; 15(5):418-23. PubMed ID: 20441435
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
[TBL] [Abstract][Full Text] [Related]
19. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.
Bjöhle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Söderberg M; Sundquist M; Walz TM; Fernö M; Bergh J; Hatschek T
Breast Cancer Res Treat; 2013 Jun; 139(3):751-8. PubMed ID: 23736998
[TBL] [Abstract][Full Text] [Related]
20. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer.
Salgado R; Junius S; Benoy I; Van Dam P; Vermeulen P; Van Marck E; Huget P; Dirix LY
Int J Cancer; 2003 Feb; 103(5):642-6. PubMed ID: 12494472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
